Sep 11, 2019 / 03:40PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
So great. So thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Pleased to have Denali with us.
Just quickly before we get going, I need to read an important disclosure statement. Please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. Or you can pick up your very own copy at the registration desk.
Questions and Answers:
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive DirectorSo I'm very pleased to have Alex Schuth with us. And Alex, I thought -- look, to start off, there've been a handful of neurology neurodegeneration companies that have come to market in the last 2 or 3 years. I thought maybe just it would be helpful to highlight what's your approach and why you think that approach is unique?
Alexander O. Schuth<
Trustpilot
